TY - JOUR T1 - Disentangling the roles of human mobility and deprivation on the transmission dynamics of COVID-19 using a spatially explicit simulation model JF - medRxiv DO - 10.1101/2020.11.25.20144139 SP - 2020.11.25.20144139 AU - C.J. Banks AU - E. Colman AU - T. Doherty AU - O. Tearne AU - M. Arnold AU - K. Atkins AU - D. Balaz AU - G. Beaunée AU - P. Bessell AU - J. Enright AU - A. Kleczkowski AU - G. Rossi AU - A.-S. Ruget AU - R.R. Kao Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/27/2020.11.25.20144139.abstract N2 - Restrictions on mobility are a key component of infectious disease controls, preventing the spread of infections to as yet unexposed areas, or to regions which have previously eliminated outbreaks. However, even under the most severe restrictions, some travel must inevitably continue, at the very minimum to retain essential services. For COVID-19, most countries imposed severe restrictions on travel at least as soon as it was clear that containment of local outbreaks would not be possible. Such restrictions are known to have had a substantial impact on the economy and other aspects of human health, and so quantifying the impact of such restrictions is an essential part of evaluating the necessity for future implementation of similar measures.In this analysis, we built a simulation model using National statistical data to record patterns of movements to work, and implement levels of mobility recorded in real time via mobile phone apps. This model was fitted to the pattern of deaths due to COVID-19 using approximate Bayesian inference. Our model is able to recapitulate mortality considering the number of deaths and datazones (DZs, which are areas containing approximately 500-1000 residents) with deaths, as measured across 32 individual council areas (CAs) in Scotland. Our model recreates a trajectory consistent with the observed data until 1st of July. According to the model, most transmission was occurring “locally” (i.e. in the model, 80% of transmission events occurred within spatially defined “communities” of approximately 100 individuals). We show that the net effect of the various restrictions put into place in March can be captured by a reduction in transmission down to 12% of its pre-lockdown rate effective 28th March. By comparing different approaches to reducing transmission, we show that, while the timing of COVID-19 restrictions influences the role of the transmission rate on the number of COVID-related deaths, early reduction in long distance movements does not reduce death rates significantly. As this movement of individuals from more infected areas to less infected areas has a minimal impact on transmission, this suggests that the fraction of population already immune in infected communities was not a significant factor in these early stages of the national epidemic even when local clustering of infection is taken into account.The best fit model also shows a considerable influence of the health index of deprivation (part of the “index of multiple deprivations”) on mortality. The most likely value has the CA with the highest level of health-related deprivation to have on average, a 2.45 times greater mortality rate due to COVID-19 compared to the CA with the lowest, showing the impact of health-related deprivation even in the early stages of the COVID-19 national epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthis work has been funded by a Roslin strategic award: ISP2 (theme 3) - BBS/E/D/20002174, by Wellcome Trust grant 209818/Z/17/Z, and by BBSRC grant BB/P010598/1Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None required (desk-based study using publicly available data).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are freely available (though in some cases subject to signing an appropriate data sharing agreement). Links to sources where these can be found are in the manuscript. ER -